PUMA
24.3.2024 09:01:26 CET | Business Wire | Press release
Globally renowned sports brand, PUMA, proudly unveiled the highly anticipated Jamaican Olympic Association kits during an unmissable showcase of speed at the ISSA Boys & Girls Championships in Kingston, Jamaica.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240324802511/en/
Sports company PUMA unveiled the Jamaican Olympic Association kits at the ISSA Boys & Girls Championships in Kingston, Jamaica. (Pictured: Shanieka Ricketts) (Photo: Business Wire)
The reveal, at the Jamaica National Stadium, came in front of more than 25,000 track enthusiasts from across the country, all gathering to feast their eyes on the future of Jamaican track & field. It served as the perfect platform to showcase the cutting-edge apparel that will adorn the fastest athletes on the planet this summer in Paris – many of whom competed at this event in their teenage years.
Jamaica’s most prestigious athletes took centre stage for the grand reveal, including the likes of double, double Olympic Champion, Elaine Thompson-Herah; the fastest woman alive at the 200 meters, Shericka Jackson; reigning Olympic Champion at the 110m hurdles Hansle Parchment; the second fastest man of all-time, Yohan Blake; former 100m World Record holder, Asafa Powell; World U-20 Triple Jump Champion Jaydon Hibbert; Rushell Clayton, Ackeem Blake and many more. They were joined side-by-side on the track by young athletes from PUMA sponsored high schools.
The ISSA Boys & Girls Championships, often referred to as "Champs," has gained immense popularity and recognition for its ability to showcase young Jamaican talent who have gone on to achieve greatness on both the domestic and international stage. The Championships not only celebrate sporting excellence but also serve as a symbol of unity, passion and pride for the Jamaican community.
"Champs is the beating heart of Jamaica. For decades, it has produced an unimaginable number of Olympians, World Champions and World Record holders, who themselves have created some of the most memorable moments in sports history. Tonight, here in Kingston, we created another,” said PUMA's Chief Executive Officer, Arne Freundt.
The new designs represent a perfect harmony of speed and fashion, reflective of the symbiotic relationship between these two giants of track & field.
Rooted in elite performance, they have been designed to evoke speed with cut lines strategically placed to accentuate the physique of the athletes whilst also providing a showstopping visual via Warpspeed graphics that emphasise the beauty of an athlete in motion. Engineered jacquard fabric is ergonomically shaped to contour the back muscles for heat reduction and breathability, with thermoadapt technology regulating body temperature to enable optimum performance.
“In their truest form these kits are an expression of speed. Speed has always been PUMA’s vantage point. It is what enables us to see the game differently, challenge convention and create moments that will live with us forever. We can’t wait to experience more in Paris this summer,” added Arne.
Maria Valdes, Chief Product Officer at PUMA, commented: “What makes these kits special is how closely they have been created in collaboration with our athletes. They are more than just a kit – they are a statement of the collective ambition shared between PUMA and Jamaica. They are a symbol of pride for the PUMA family, and we hope that they become a symbol of pride for Jamaicans this summer and long into the future.”
To find out more about PUMA follow @pumarunning on Instagram.
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 21,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240324802511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
